Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC

Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non –small-cell lung cancer patients.

Source: CancerNetwork - April 8, 2019 Category: Cancer & Oncology Authors: Lecia V. Sequist, MD, MPH Source Type: news